Vast Therapeutics

Funding and NIH signals

• NIH award NIH awarded $1M (SBIR Phase II 1R44AI191890-01A1, new, notice Sep 14, 2026); 3 NIH awards totaling $2.94M in the last 12 months. NIH RePORTER 1R44AI191890-01A1 (Sep 14, 2026)
  Evidence (3 events)

  • Sep 14, 2026 · NIH RePORTER 1R44AI191890-01A1
    Organization: VAST THERAPEUTICS, INC.; City/State: Morrisville, NC; Project number: 1R44AI191890-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Inhaled Nitric-Oxide Releasing Prodrug to Treat Drug Resistant Klebsiella pneumoniae Infections; Organization type: Domestic For-Profits
  • Aug 14, 2026 · NIH RePORTER 5R44AI186617-02
    Organization: VAST THERAPEUTICS, INC.; City/State: Morrisville, NC; Project number: 5R44AI186617-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 950129; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Nebulized ALX1 as a Treatment for Difficult Non-tuberculous Mycobacterial Lung Infections; Organization type: Domestic For-Profits
  • May 26, 2026 · NIH RePORTER 5R44AI184225-02
    Organization: VAST THERAPEUTICS, INC.; City/State: Morrisville, NC; Project number: 5R44AI184225-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-26; FY total cost (award amount): 988594; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals